期刊文献+
共找到118篇文章
< 1 2 6 >
每页显示 20 50 100
Hepatitis B virus reactivation associated with antirheumatic therapy: risk and prophylaxis recommendations 被引量:12
1
作者 Shunsuke Mori Shigetoshi Fujiyama 《World Journal of Gastroenterology》 SCIE CAS 2015年第36期10274-10289,共16页
Accompanying the increased use of biological and non-biological antirheumatic drugs,a greater number of cases of hepatitis B virus(HBV) reactivation have been reported in inactive hepatitis B surface antigen(HBs Ag) c... Accompanying the increased use of biological and non-biological antirheumatic drugs,a greater number of cases of hepatitis B virus(HBV) reactivation have been reported in inactive hepatitis B surface antigen(HBs Ag) carriers and also in HBs Ag-negative patients who have resolved HBV infection. The prevalence of resolved infection varies in rheumatic disease patients,ranging from 7.3% to 66%. Through an electronic search of the Pub Med database,we found that among 712 patients with resolved infection in 17 observational cohort studies,12 experienced HBV reactivation(1.7%) during biological antirheumatic therapy. Reactivation rates were 2.4% for etanercept therapy,0.6% for adalimumab,0% for infliximab,8.6% for tocilizumab,and 3.3% for rituximab. Regarding non-biological antirheumatic drugs,HBV reactivation was observed in 10 out of 327 patients with resolved infection from five cohort studies(3.2%). Most of these patients received steroids concomitantly. Outcomes were favorable in rheumatic disease patients. A number of recommendations have been established,but most of the supporting evidence was derived from the oncology and transplantation fields. Compared with patients in these fields,rheumatic disease patients continue treatment with multiple immunosuppressants for longer periods. Optimal frequency and duration of HBV-DNA monitoring and reliable markers for discontinuation of nucleoside analogues should be clarified for rheumatic disease patients with resolved HBV infection. 展开更多
关键词 HEPATITIS B VIRUS antirheumatic THERAPY RESOLVED h
下载PDF
Perioperative management of the patient with rheumatoid arthritis 被引量:6
2
作者 Megan L Krause Eric L Matteson 《World Journal of Orthopedics》 2014年第3期283-291,共9页
A multidisciplinary approach is required to care for patients with rheumatoid arthritis(RA)in the perioperative period.In preparation for surgery,patients must have a cardiovascular risk assessment performed due to th... A multidisciplinary approach is required to care for patients with rheumatoid arthritis(RA)in the perioperative period.In preparation for surgery,patients must have a cardiovascular risk assessment performed due to the high risk of heart disease in patients with RA.Treatment of RA is with immunomodulatory medications,which present unique challenges for the perioperative period.Currently,there is no consensus on how to manage disease modifying antirheumatic drug(DMARD)therapy in the perioperative setting.Much of the data to guide therapy is based on retrospective cohort data.Choices regarding DMARDs require an individualized approach with collaboration between surgeons and rheumatologists.Consensus regarding biologic therapy is to hold the therapy in the perioperative period with the length of time dictated by the half-life of the medication.Special attention is required at the time of surgery for potential need for stress dose steroids.Further,there must be close communication with anesthesiologists in terms of airway management particularly in light of the risk for cervical spine disease.There are no consensus guidelines regarding the requirement for cervical spine radiographs prior to surgery.However,history and exam alone cannot be relied upon toidentify cervical spine disease.Patients with RA who undergo joint replacement arthroplasty are at higher risk for infection and dislocation compared to patients with osteoarthritis,necessitating particular vigilance in postoperative follow up.This review summarizes available evidence regarding perioperative management of patients with RA. 展开更多
关键词 RHEUMATOID ARTHRITIS PERIOPERATIVE management Disease MODIFYING antirheumatic drugs Tumor NECROSIS factor inhibitors POSTSURGICAL complications
下载PDF
Evolution of treatment options for juvenile idiopathic arthritis
3
作者 Tao Ren Jia-Hui Guan +2 位作者 Yu Li Nan-Nan Li Zheng Li 《World Journal of Orthopedics》 2024年第9期831-835,共5页
A recent study published in World J Clin Cases addressed the optimal non-steroidal anti-inflammatory drugs(NSAIDs)for juvenile idiopathic arthritis(JIA).Herein,we outline the progress in drug therapy of JIA.NSAIDs hav... A recent study published in World J Clin Cases addressed the optimal non-steroidal anti-inflammatory drugs(NSAIDs)for juvenile idiopathic arthritis(JIA).Herein,we outline the progress in drug therapy of JIA.NSAIDs have traditionally been the primary treatment for all forms of JIA.NSAIDs are symptom-relief medications,and well tolerated by patients.Additionally,the availability of selective NSAIDs further lower the gastrointestinal adverse reactions compared with traditional NSAIDs.Glucocorticoid is another kind of symptom-relief medications with potent anti-inflammatory effect.However,the frequent adverse events limit the clinical use.Both NSAIDs and glucocorticoid fail to ease or pre-vent joint damage,and the breakthrough comes along with the disease-mo-difying antirheumatic drugs(DMARDs).DMARDs can prevent disease pro-gression and reduce joint destruction.Particularly,the emergence of biologic DMARDs(bDMARDs)has truly revolutionized the therapeutics of JIA,compared with conventional synthetic DMARDs.As a newly developed class of drugs,the places of most bDMARDs in the management of JIA remain to be well estab-lished.Nevertheless,the continuous evolution of bDMARDs raises hopes of improving long-term disease outcomes for JIA. 展开更多
关键词 Juvenile idiopathic arthritis TREATMENT Non-steroidal anti-inflammatory drug Disease-modifying antirheumatic drug EVOLUTION
下载PDF
抗风湿药物对生育力、妊娠及哺乳的影响 被引量:6
4
作者 赵云 张奉春 《中华临床免疫和变态反应杂志》 2013年第2期188-192,共5页
风湿免疫病患者妊娠期用药受到日益关注。本文就非甾体抗炎药、糖皮质激素、甲氨蝶呤、环磷酰胺、硫唑嘌呤、柳氮磺胺吡啶、羟氯喹、来氟米特、环孢素A、吗替麦考酚酯、他克莫司,以及英夫利昔单抗、依那西普、阿达木单抗利妥昔单抗等生... 风湿免疫病患者妊娠期用药受到日益关注。本文就非甾体抗炎药、糖皮质激素、甲氨蝶呤、环磷酰胺、硫唑嘌呤、柳氮磺胺吡啶、羟氯喹、来氟米特、环孢素A、吗替麦考酚酯、他克莫司,以及英夫利昔单抗、依那西普、阿达木单抗利妥昔单抗等生物制剂对患者的生育力、妊娠及哺乳的影响进行综述,以期为临床提供规范的用药指导。 展开更多
关键词 抗风湿药 生育力 妊娠 哺乳
下载PDF
Role of JAK-STAT signaling pathway in pathogenesis and treatment of primary Sjögren’s syndrome 被引量:1
5
作者 Mucong Li Mengtao Li +4 位作者 Lin Qiao Chanyuan Wu Dong Xu Yan Zhao Xiaofeng Zeng 《Chinese Medical Journal》 SCIE CAS CSCD 2023年第19期2297-2306,共10页
Primary Sjögren’s syndrome(pSS)is a systemic autoimmune disease with high prevalence and possible poor prognosis.Though the pathogenesis of pSS has not been fully elucidated,B cell hyperactivity is considered as... Primary Sjögren’s syndrome(pSS)is a systemic autoimmune disease with high prevalence and possible poor prognosis.Though the pathogenesis of pSS has not been fully elucidated,B cell hyperactivity is considered as one of the fundamental abnormalities in pSS patients.It has long been identified that Janus kinases-signal transducer and activator of transcription(JAK-STAT)signaling pathway contributes to rheumatoid arthritis and systemic lupus erythematosus.Recently,increasing numbers of studies have provided evidence that JAK-STAT pathway also has an important role in the pathogenesis of pSS via direct or indirect activation of B cells.Signal transducer and activator of transcription 1(STAT1),STAT3,and STAT5 activated by various cytokines and ribonucleic acid contribute to pSS development,respectively or synergically.These results reveal the potential application of Janus kinase inhibitors for treatment of pSS,which may fundamentally improve the quality of life and prognosis of patients with pSS. 展开更多
关键词 Primary Sjögren’s syndrome JAK-STAT pathway Janus kinase inhibitors Disease-modifying antirheumatic drugs
原文传递
HPLC-DAD/MS法测定抗风湿中成药中非法添加10种抗风湿化学成分 被引量:5
6
作者 杨丽蓉 赵红磊 +3 位作者 赵海鹏 邱凯 陈燕 王明琪 《中国药品标准》 CAS 2018年第3期235-240,共6页
目的:建立检测抗风湿中成药中非法添加10种抗风湿化学成分的HPLC-DAD方法,并用MS/MS进行了化合物的归属分析。方法:用C18色谱柱(4.6 mm×250 mm,5μm),以0.02 mol·L^(-1)乙酸铵(含0.05%乙酸)水溶液为流动相A,以乙腈为流动相B,... 目的:建立检测抗风湿中成药中非法添加10种抗风湿化学成分的HPLC-DAD方法,并用MS/MS进行了化合物的归属分析。方法:用C18色谱柱(4.6 mm×250 mm,5μm),以0.02 mol·L^(-1)乙酸铵(含0.05%乙酸)水溶液为流动相A,以乙腈为流动相B,梯度洗脱,波长240 nm,流速1.0 mL·min^(-1),进行HPLC定性定量分析;再采用串联四极杆质谱的MRM模式检测,进行化合物归属分析,检测添加在中成药中的对乙酰氨基酚、甲氧苄啶、氨基比林、吡罗昔康、萘普生、双氯芬酸钠、醋酸泼尼松、吲哚美辛、保泰松、布洛芬10种化学成分。结果:10种抗风湿性化学成分液相检测的线性范围宽,相关性好,r≥0.999 2,方法精密度符合要求;回收率在98.0%~100.9%之间;精密度、稳定性均符合要求;检测限为0.05~0.5μg·mL^(-1);定量限为0.1~1.8μg·mL^(-1)。结论:本方法专属性强,操作简单,快捷,可作为中成药中非法添加以上10种抗风湿性化学成分的有效检测方法。 展开更多
关键词 高效液相色谱法 液质联用 中成药 抗风湿 非法添加
下载PDF
治疗207例类风湿关节炎的药物利用及成本分析 被引量:4
7
作者 朱秀美 郭代红 +2 位作者 任浩洋 张志萍 王东晓 《中国医院用药评价与分析》 2002年第3期159-160,共2页
目的 :对目前临床治疗类风湿关节炎的药物利用和费用进行评价。方法 :采用回顾性调查方法分析我院1999年1月~2000年6月类风湿关节炎住院患者的药物利用及成本消耗情况。结果 :在207例中 ,总有效率为99%。用药方式以四药联用最多 ,占31 ... 目的 :对目前临床治疗类风湿关节炎的药物利用和费用进行评价。方法 :采用回顾性调查方法分析我院1999年1月~2000年6月类风湿关节炎住院患者的药物利用及成本消耗情况。结果 :在207例中 ,总有效率为99%。用药方式以四药联用最多 ,占31 40 % ;给药途径以口服最多 ,价格相对低廉。结论 :治疗类风湿关节炎药物以口服为主。治疗模式应根据具体病情和预后指征合理用药。 展开更多
关键词 类风湿关节炎 治疗 药物利用 成本分析 非甾体抗炎药
下载PDF
Use of biologic agents for rheumatic diseases in pregnancy
8
作者 Yesim Garip 《World Journal of Rheumatology》 2015年第2期50-58,共9页
Biologic agents have ushered a new era in the treatment of inflammatory rheumatic diseases.In recent years,several biologic agents have been approved by food and drug administration and have significantly improved out... Biologic agents have ushered a new era in the treatment of inflammatory rheumatic diseases.In recent years,several biologic agents have been approved by food and drug administration and have significantly improved outcomes for patients with immune mediatedinflammatory disorders including rheumatic and inflammatory bowel diseases.The most common used biologic therapeutic agents are tumor necrosis factor inhibitors(etanercept,infliximab,adalimumab,certolizumab pegol,and golimumab),an interleukin(IL)-6 inhibitor(tocilizumab),an IL-1 receptor antagonist(anakinra),an anti-CD-20 antibody(rituximab),and a T cell costimulation modulator(abatacept).Their use during pregnancy has been controversial because of absence of controlled studies which have enrolled pregnant women.This brief overview provides published data on use of biologic agents for the treatment of rheumatic diseases in pregnancy. 展开更多
关键词 ANKYLOSING SPONDYLITIS RHEUMATOID ARTHRITIS PREGNANCY Disease-modifying antirheumatic drugs
下载PDF
Treatment Adherence of Patients with Rheumatoid Arthritis during COVID-19 Pandemic
9
作者 Syamasis Bandyopadhyay Susobhan Mondal 《Open Journal of Rheumatology and Autoimmune Diseases》 2021年第3期106-114,共9页
India is no exception to the economic setback due to coronavirus disease 2019 (COVID-19). Loss of jobs and income dramatically impacts the health care cost of chronic disease management. Rheumatoid arthritis is a chro... India is no exception to the economic setback due to coronavirus disease 2019 (COVID-19). Loss of jobs and income dramatically impacts the health care cost of chronic disease management. Rheumatoid arthritis is a chronic condition with a high-cost implication. With the outbreak of COVID-19, there is uncertainty about continuing immunosuppressive therapy for rheumatoid arthritis for several reasons. In this milieu, we undertook a prospective observational study to observe the use of Janus Kinase (JAK) inhibitors in a hospital-based rheumatology service in Eastern India during the pandemic period (21 March 2020 to 31 July 2020). Forty-two patients with rheumatoid arthritis were receiving treatment with JAK inhibitors. Twenty-four patients visited the Outpatient Department (OPD) during the COVID-19 pandemic. All of them were COVID-negative, but few of the patients had influenza-like symptoms. Patients faced up to a 25% reduction in their annual income during the COVID-19 pandemic. Of 24 patients, four patients had stopped treatment with JAK inhibitors owing to financial constraints or initial non-availability of medications during the lockdown. In this study, adherence to JAK inhibitors was substantially high even in the face of income curtailment during the COVID-19 pandemic. 展开更多
关键词 COVID-19 Rheumatoid Arthritis Janus Kinase JAK Inhibitors Disease-Modifying antirheumatic Drugs ADHERENCE COST
下载PDF
What is the best biological treatment for rheumatoid arthritis? A systematic review of effectiveness
10
作者 Jéssica Barreto dos Santos Juliana de Oliveira Costa +6 位作者 Haliton Alves de Oliveira Junior Lívia Lovato Pires Lemos Vnia Eloisa de Araújo Marina Amaral de Avila Machado Alessandra Maciel Almeida Francisco de Assis Acurcio Juliana Alvares 《World Journal of Rheumatology》 2015年第2期108-126,共19页
AIM:To evaluate the effectiveness of the biological disease-modifying antirheumatic drugs(b DMARD) in the treatment of rheumatoid arthritis through a systematic review of observational studies.METHODS:The studies were... AIM:To evaluate the effectiveness of the biological disease-modifying antirheumatic drugs(b DMARD) in the treatment of rheumatoid arthritis through a systematic review of observational studies.METHODS:The studies were searched in the Pub Med,EMBASE,Cochrane Controlled Trials Register and LILACS databases(until August 2014),in the grey literature and conducted a manual search.The assessed criteria of effectiveness included the EULAR,the disease activity score(DAS),the Clinical Disease Activity Index,the Simplified Disease Activity Index,the American College of Rheumatology and the Health Assessment Questionnaire.The meta-analysis was performed with Review Manager 5.2 software using a random effects model.A total of 35 studies were included in this review.RESULTS:The participants anti-tumor necrosis factor inhibitors(TNF) nave,who used adalimumab(P = 0.0002) and etanercept(P = 0.0006) exhibited greater good EULAR response compared to the participants who used infliximab.No difference was detected between adalimumab and etanercept(P = 0.05).The participants who used etanercept exhibited greater remission according to DAS28 compared to the participants who used infliximab(P = 0.01).No differences were detected between adalimumab and infliximab(P = 0.12) or etanercept(P = 0.79).Better results were obtained with b DMARD associated with methotrexate than with b DMARD alone.The good EULAR response and DAS 28 was better for combination with methotrexate than b DMARD monotherapy(P = 0.03 e P < 0.00001).In cases of therapeutic failure,the participants who used rituximab exhibited greater DAS28 reduction compared to those who used anti-TNF agents(P = 0.0002).The participants who used etanercept achieved greater good EULAR response compared to those who did not use that drug(P = 0.007).Studies that assessed reduction of the CDAI score indicated the superiority of abatacept over rituximab(12.4 vs +1.7) and anti-TNF agents(7.6 vs 8.3).The present systematic review with meta-analysis found that relative to anti-TNF treatmentnave 展开更多
关键词 Systematic review META-ANALYSIS Effecti-veness Biological disease-modifying antirheumatic drugs Rheumatoid arthritis
下载PDF
甲氨蝶呤联合传统DMARDs与联合生物制剂治疗RA的疗效比较 被引量:2
11
作者 刘念 张秀灵 +3 位作者 尚静静 毛绍园 邹桂香 段新旺 《南昌大学学报(医学版)》 CAS 2017年第6期32-36,共5页
目的比较甲氨蝶呤联合传统改善病情的抗风湿药(DMARDs)与联合生物制剂治疗类风湿关节炎(RA)的临床疗效。方法将单用甲氨蝶呤治疗3个月失败的46例RA患者按随机数字表法分为A组(21例)和B组(25例)。A组给予甲氨蝶呤片联合传统DMARDs(来氟... 目的比较甲氨蝶呤联合传统改善病情的抗风湿药(DMARDs)与联合生物制剂治疗类风湿关节炎(RA)的临床疗效。方法将单用甲氨蝶呤治疗3个月失败的46例RA患者按随机数字表法分为A组(21例)和B组(25例)。A组给予甲氨蝶呤片联合传统DMARDs(来氟米特片+羟氯喹片)治疗,B组给予甲氨蝶呤片联合生物制剂(注射用重组人Ⅱ型肿瘤坏死因子受体)治疗。观察2组治疗前和治疗3、6个月后晨僵持续时间,关节肿胀数、关节压痛数、静息痛次数,美国健康评估问卷(HAQ)评分、28个关节疾病活动度评分系统(DAS28)评分,患者对目前疾病总体状况的自我评价评分、医生对患者疾病总体状况的评分及实验室指标[(WBC)计数,血清丙氨酸氨基转移酶(ALT)、肌酐(Cr)、红细胞沉降率(ESR)、C-反应蛋白(CRP)]的变化。结果 2组治疗3个月后WBC计数,血清ALT、Cr、CRP水平与治疗6个月后比较差异无统计学意义(P>0.05)。与同组治疗3个月后比较,A、B 2组治疗6个月后晨僵持续时间缩短,关节肿胀数、关节压痛数、静息痛次数均明显减少,HAQ评分、DAS28评分、患者对目前疾病总体状况的自我评价评分、医生对患者疾病总体状况的评分及血清ESR水平均明显降低(均P<0.05);与A组比较,B组治疗3、6个月治疗后晨僵持续时间显著缩短,关节肿胀数、关节压痛数、静息痛次数均明显减少,HAQ评分、DAS28评分、患者对目前疾病总体状况的自我评价评分、医生对患者疾病总体状况的评分及血清ESR水平均明显降低(均P<0.05)。结论甲氨蝶呤联合传统DMARDs与联合生物制剂对单用甲氨蝶呤治疗3个月失败的患者均有效果,但甲氨蝶呤与联合生物制剂治疗效果更优于联合传统DMARDs。 展开更多
关键词 类风湿关节炎 甲氨蝶呤 抗风湿药 生物制剂 疗效
下载PDF
Hepatitis B virus reactivation in rheumatoid arthritis 被引量:1
12
作者 Ya-Li Wu Jing Ke +1 位作者 Bao-Yu Zhang Dong Zhao 《World Journal of Clinical Cases》 SCIE 2022年第1期12-22,共11页
Rheumatoid arthritis(RA)is an autoimmune disease characterized by proliferative synovitis,which can cause cartilage and bone damage as well as functional limitations.Disease-modifying anti-rheumatic drugs have signifi... Rheumatoid arthritis(RA)is an autoimmune disease characterized by proliferative synovitis,which can cause cartilage and bone damage as well as functional limitations.Disease-modifying anti-rheumatic drugs have significantly improved the prognosis of RA patients.However,people with RA,when combined with hepatitis B virus(HBV)infection,may experience reactivation of HBV during treatment with anti-rheumatic drugs.The outcome of HBV reactivation(HBVr)varies from liver inflammation to liver failure,while insufficient HBV screening in RA patients has been reported in various countries.Therefore,it is necessary to identify patients at high risk before starting immunosuppressive therapy.The immune response plays an important role in anti-HBV infection.However,most anti-rheumatic drugs exert an inhibitory effect on the body’s immune system,resulting in HBVr.Therefore,it is necessary to conduct a comprehensive evaluation based on host factors,viral factors,and drug factors.In this paper,we summarize the mechanism of HBVr,the risk of HBVr caused by anti-rheumatic drugs,and the appropriate diagnosis and treatment process for RA patients so that clinicians can have a more comprehensive understanding of HBVr in RA patients. 展开更多
关键词 Rheumatoid arthritis Hepatitis B virus reactivation Disease-modifying antirheumatic drugs Risk factors
下载PDF
Hepatitis B virus infection reactivation in patients under immunosuppressive therapies:Pathogenesis,screening,prevention and treatment 被引量:1
13
作者 Anna Maria Spera 《World Journal of Virology》 2022年第5期275-282,共8页
With a 5.3%of the global population involved,hepatitis B virus(HBV)is a major public health challenge requiring an urgent response.After a possible acute phase,the natural history of HBV infection can progress in chro... With a 5.3%of the global population involved,hepatitis B virus(HBV)is a major public health challenge requiring an urgent response.After a possible acute phase,the natural history of HBV infection can progress in chronicity.Patients with overt or occult HBV infection can undergo HBV reactivation(HBVr)in course of immunosuppressive treatments that,apart from oncological and hematological diseases,are also used in rheumatologic,gastrointestinal,neurological and dermatological settings,as well as to treat severe acute respiratory syndrome coronavirus 2 infection.The risk of HBV reactivation is related to the immune status of the patient and the baseline HBV infection condition.The aim of the present paper is to investigate the risk of HBVr in those not oncological settings in order to suggest strategies for preventing and treating this occurrence.The main studies about HBVr for patients with occult hepatitis B infection and chronic HBV infection affected by non-oncologic diseases eligible for immunosuppressive treatment have been analyzed.The occurrence of this challenging event can be reduced screening the population eligible for immunosuppressant to assess the best strategies according to any virological status.Further prospective studies are needed to increase data on the risk of HBVr related to newer immunomodulant agents employed in non-oncological setting. 展开更多
关键词 Hepatitis B Virus infection REACTIVATION Occult B infection Chronic B infection IMMUNOSUPPRESSION Disease-modifying antirheumatic drugs
下载PDF
HPLC法检测抗风湿类中成药中添加的尼美舒利和吡罗昔康 被引量:2
14
作者 郭飞宇 李存金 《江西中医学院学报》 2010年第2期58-60,共3页
目的:建立HPLC法检测抗风湿类中成药中非法添加化学物质尼美舒利和吡罗昔康的检验方法.方法:采用Diamonsil C18色谱柱,流动相:甲醇-1.36g/L磷酸二氢钾溶液(54∶46),流速:1.0 ml/min,柱温:25 ℃,检测波长:338 nm.结果:尼美舒利... 目的:建立HPLC法检测抗风湿类中成药中非法添加化学物质尼美舒利和吡罗昔康的检验方法.方法:采用Diamonsil C18色谱柱,流动相:甲醇-1.36g/L磷酸二氢钾溶液(54∶46),流速:1.0 ml/min,柱温:25 ℃,检测波长:338 nm.结果:尼美舒利对照品线性范围150.06~400.16 μg/ml,r=0.999 9;吡罗昔康对照品线性范围42.24~112.64 μg/ml,r=0.999 9.平均回收率分别为98.74%,99.04%,RSD分别为0.7%,0.9%(n=6).结论:本方法灵敏度高,操作简便、准确,可用于定性和定量检测抗风湿类中成药中非法添加的化学物质尼美舒利和吡罗昔康. 展开更多
关键词 高效液相色谱法 抗风湿 中成药 尼美舒利 吡罗昔康
下载PDF
风湿病的药物治疗 被引量:1
15
作者 方忠宏 曾宏辉 《药学进展》 CAS 2000年第4期215-217,共3页
非甾体抗炎药的使用因其不良反应而逐渐减少 ,本文分类介绍了若干风湿病药物疗法及可能产生的副作用。新开发的环氧酶 2抑制剂及生物技术药物不仅可减少胃肠道副作用 ,对风湿病的早期治疗有良好疗效 ,且可减少关节炎引起的功能丧失 ;临... 非甾体抗炎药的使用因其不良反应而逐渐减少 ,本文分类介绍了若干风湿病药物疗法及可能产生的副作用。新开发的环氧酶 2抑制剂及生物技术药物不仅可减少胃肠道副作用 ,对风湿病的早期治疗有良好疗效 ,且可减少关节炎引起的功能丧失 ;临床实践表明联合用药优于单药治疗 ,既提高了疗效 ,又减少了副作用。 展开更多
关键词 抗风湿病药 环氧酶抑制剂 NSAIDS 联合用药
下载PDF
Production of Gel with Menthol, Benzocaine and Procaine HCl for Topical Application in Rheumatoid Arthritis Patients 被引量:1
16
作者 B. Angelovska S. Maleska- Stoj adinovikj +1 位作者 E. Drakalska B. Gjorgjeska 《Journal of Pharmacy and Pharmacology》 2017年第5期245-248,共4页
Antirheurnatic and analgesics drugs are the most commonly prescribed medications for treatment of acute and chronic pain. Frequent application of these agents often causes adverse effects. So, in order to avoid the in... Antirheurnatic and analgesics drugs are the most commonly prescribed medications for treatment of acute and chronic pain. Frequent application of these agents often causes adverse effects. So, in order to avoid the incidence of side effects, topical analgesics are treatment of choice for localized muscle pain. Topical analgesics offer the potential to provide the same analgesic relief provided by oral analgesics but with minimal adverse systemic effects. The aim of this study is to present the preparation and characterization of topical analgesic gel named "Russian water". Gel is composed of Menthol, Benzocaine, Procaine HCl as topical analgesic agents indicated for temporary relief of pain. Obtained results showed prolonged analgesic effect compared with liquid ethanol solution composed of the same components. 展开更多
关键词 Pain GEL Russian water antirheumatic analgesic.
下载PDF
Therapeutic Efficacy Observation on Acupuncture plus Medication for Rheumatoid Arthritis 被引量:1
17
作者 梁永瑛 郭艳明 +2 位作者 顾钧青 周帅亮 韩丑萍 《Journal of Acupuncture and Tuina Science》 2012年第4期209-212,共4页
Objective: To observe the clinical efficacy of acupuncture plus medication for rheumatic arthritis (RA). Methods: A total of 80 RA cases were randomized into an observation group and a control group, 40 in each gr... Objective: To observe the clinical efficacy of acupuncture plus medication for rheumatic arthritis (RA). Methods: A total of 80 RA cases were randomized into an observation group and a control group, 40 in each group. Cases in the observation group received antirheumatic agents and acupuncture therapy, whereas cases in the control group received antirheumatic agents alone. The therapeutic efficacies were observed after 3 sessions of treatment. Results: After the treatment, patients in the observation group had significant improvement in their morning stiffness time, average grip of both hands, joint tenderness and joint swelling, showing statistical significances (P〈0.01); symptoms of patients in the control group were also remarkably improved (P〈0.01, P〈0.05). Compared with the control group, the improvements in joint tenderness and average grip of both hands in the observation group were more significant (P〈0.05). After treatment, the Health Assessment Questionnaire (HAQ) points were significantly improved in both groups, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) in both groups were remarkably reduced (P〈0.01, P〈0.05); however, compared with the control group, the CRP decrease in the observation group was more significant (P〈0.05). Conclusion: Acupuncture plus antirheumatic agents can effectively increase the RA patients' activities of daily living (ADL) and thus improve their quality of life. 展开更多
关键词 Acupuncture Therapy Acupuncture Medication Combined antirheumatic Agents Arthritis Rheumatoid Activities of Daily Living
原文传递
氟罗布芬的合成 被引量:1
18
作者 王未东 张奕华 《中国医药工业杂志》 CAS CSCD 北大核心 2005年第3期133-134,共2页
用衣康酸酐经异构化、还原、环合得到甲基丁二酸酐,与由2,4-二氟苯胺经Gomberg-Bachmann-Hey反应得到的2,4-二氟联苯进行付-克反应,制得COX/5-LO双重抑制剂氟罗布芬,总收率49%(以衣康酸酐计)。
关键词 氟罗布芬 类风湿性关节炎治疗药物 合成
下载PDF
Observation on the Therapeutic Effect of Heatclearing and Dampness-eliminating Dredging Collaterals Combined with Papaya Antirheumatic Pills on Treatment of Damp-heat Obstructive Ankylosing Spondylitis
19
作者 Youling Huang 《Journal of Clinical and Nursing Research》 2020年第2期57-60,共4页
Objective:Therapeutic effect of heatclearing and dampness-eliminating dredging collaterals combined with papaya antirheumatic pills on treatment of damp-heat obstructive ankylosing spondylitis.Methods:A total of 200 p... Objective:Therapeutic effect of heatclearing and dampness-eliminating dredging collaterals combined with papaya antirheumatic pills on treatment of damp-heat obstructive ankylosing spondylitis.Methods:A total of 200 patients with ankylosing spondylitis who were treated in our hospital from January 2018 to October 2019 were selected as the research objects and randomly divided into 2 groups,each with 100 patients.The control group was treated with leflunomide+papaya antirheumatic pills,and the observation group was treated with self-drafted recipe of heat-clearing and dampness-eliminating,the curative effect,visual analogue score(VAS),barthel AS function index(BASFI)score,biochemical indicators and adverse reactions between the two groups were compared.Results:After 12 weeks of treatment,the efficacy of the observation group was higher than that of the control group.The pain score,BASFI score,and biochemical index were lower than those of the control group,and the differences were statistically significant(P<0.05);There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Heat-clearing and dampnesseliminating dredging collaterals combined with papaya antirheumatic pills is effective in the treatment of damp-heat obstructive ankylosing spondylitis,which is beneficial to reduce the degree of pain and inflammation of the affected area,helps patients remain active,and improves activities of daily living. 展开更多
关键词 DAMP-HEAT OBSTRUCTIVE ankylosing spondylitis Heat-clearing and dampness-eliminating dredging COLLATERALS PAPAYA antirheumatic PILLS Degree of pain The biochemical index
下载PDF
抗风湿中药胶囊剂中醋酸泼尼松的定性鉴别
20
作者 吴雨川 刘天扬 +1 位作者 姜连阁 白政忠 《黑龙江医药》 CAS 2004年第4期249-250,共2页
目的:市售抗风湿药中怀疑含有激素物质,通过 TLC 法、HPLC 法鉴别药物中是否含有激素。方法:参照文献方法中泼尼松及其它甾体抗炎药的 TLC 方法以及醋酸泼尼松 HPLC 方法进行实验。结论:经 TLC 显色、HPLC 保留时间、以及 DAD 获得的 UV... 目的:市售抗风湿药中怀疑含有激素物质,通过 TLC 法、HPLC 法鉴别药物中是否含有激素。方法:参照文献方法中泼尼松及其它甾体抗炎药的 TLC 方法以及醋酸泼尼松 HPLC 方法进行实验。结论:经 TLC 显色、HPLC 保留时间、以及 DAD 获得的 UV 图比较,确证抗风湿中药胶囊中含有醋酸泼尼。 展开更多
关键词 抗风湿药 中药 胶囊剂 醋酸泼尼松 定性鉴别
下载PDF
上一页 1 2 6 下一页 到第
使用帮助 返回顶部